OppHub America Desk · · Source: yahoo-megacap-tickers
Eli Lilly $LLY Surges on Strong Q2 Sales, Weight-Loss Drug Demand
Watch Eli Lilly (NYSE: LLY) as its strong quarterly performance and updated guidance signal continued investor confidence in its weight-loss drug pipeline.
Based on reporting from yahoo-megacap-tickers.
Eli Lilly's (NYSE: LLY) shares climbed Wednesday after the pharmaceutical giant reported a robust second-quarter earnings beat, driven by soaring demand for its weight-loss drugs Mounjaro and Zepbound. The company raised its full-year revenue guidance, underscoring the strong market appetite for its pharmaceutical innovations. Investors are closely watching the company's next steps in expanding its portfolio and meeting the vast demand for its GLP-1 treatments.
Market context for this story
As of: Regular HoursLoading quotes…
Informational only — not investment advice. Full markets →
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
$LLYLilly (Eli)
TradingView
Live chart & market data via TradingView · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/LLY and related $XLV. Not investment advice.
Eli Lilly (NYSE: $LLY+WL) experienced a significant uplift in its stock price on Wednesday following a strong second-quarter earnings report that exceeded analyst expectations. The company's revenue surged 48% to $23 billion, propelled by a substantial increase in sales from its Mounjaro and Zepbound weight-loss medications. Combined, these drugs generated nearly $15 billion in quarterly sales, with worldwide volume up 60% despite a 13% price decrease.
U.S. Mounjaro sales alone jumped 91% year-over-year to $9.9 billion, while Zepbound sales reached $4.9 billion, marking a 46% increase. International revenue for Mounjaro also saw significant growth, climbing 172%. These figures contributed to Eli Lilly raising its full-year revenue guidance to between $85 billion and $87 billion.
The company is also preparing for the future, planning a May 2026 Business Line Application (BLA) filing for retatrutide, its next-generation weight-loss drug. The robust performance and forward-looking strategy highlight Eli Lilly's dominant position in the GLP-1 market.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Based on reporting from yahoo-megacap-tickers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).